These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 3841034)

  • 21. The importance of vasopressin in the development and maintenance of DOC-salt hypertension in the rat.
    Crofton JT; Share L; Shade RE; Lee-Kwon WJ; Manning M; Sawyer WH
    Hypertension; 1979; 1(1):31-8. PubMed ID: 544512
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Brain vasopressin and sodium appetite.
    Flynn FW; Kirchner TR; Clinton ME
    Am J Physiol Regul Integr Comp Physiol; 2002 Apr; 282(4):R1236-44. PubMed ID: 11893630
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evidence against a role of vasopressin in the maintenance of high blood pressure in mineralocorticoid and renovascular hypertension.
    Rabito SF; Carretero OA; Scicli AG
    Hypertension; 1981; 3(1):34-8. PubMed ID: 7009426
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Synthesis and some pharmacological properties of 18 potent O-alkyltyrosine-substituted antagonists of the vasopressor responses to arginine-vasopressin.
    Manning M; Lammek B; Bankowski K; Seto J; Sawyer WH
    J Med Chem; 1985 Oct; 28(10):1485-91. PubMed ID: 4045923
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Difference between male and female rats in vasopressor response to arginine vasopressin.
    László FA; Varga C; Papp A; Pávó I; Fahrenholz F
    Acta Physiol Hung; 1993; 81(2):137-45. PubMed ID: 8197870
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Development of high sodium renal hypertension during chronic blockade of the vascular effects of vasopressin.
    Hinojosa C; Haywood JR
    J Pharmacol Exp Ther; 1986 Aug; 238(2):492-6. PubMed ID: 2874211
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Blood pressure effects of intravenous apomorphine in conscious deoxycorticosterone-acetate salt-hypertensive rats.
    Toscano CF; Lahlou S
    J Cardiovasc Pharmacol; 2003 Dec; 42(6):772-81. PubMed ID: 14639100
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cardiovascular hemodynamics and vasopressin blockade in DOCA-salt hypertensive rats.
    Yamamoto J; Yamane Y; Umeda Y; Yoshioka T; Nakai M; Ikeda M
    Hypertension; 1984; 6(3):397-407. PubMed ID: 6735459
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prolonged inhibition of pressor response to vasopressin by a potent specific antagonist, [1-(beta-mercapto-beta, beta-cyclopentamethylenepropionic acid) 2-(O-methyl)tyrosine]arginine-vasopressin.
    Pang CC; Leighton KM
    Can J Physiol Pharmacol; 1981 Sep; 59(9):1008-12. PubMed ID: 6895346
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Endocrine control of salt and water excretion: the role of vasopressin in DOCA-salt hypertension.
    Hofbauer KG; Mah SC; Baum HP; Hänni H; Wood JM; Kraetz J
    J Cardiovasc Pharmacol; 1984; 6 Suppl 1():S184-91. PubMed ID: 6204139
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antidiuretic and pressor actions of vasopressin in age-dependent DOCA-salt hypertension.
    Zicha J; Kunes J; Lébl M; Pohlová I; Slaninová J; Jelínek J
    Am J Physiol; 1989 Jan; 256(1 Pt 2):R138-45. PubMed ID: 2912206
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of vasopressin in clinical hypertension and congestive cardiac failure: interaction with the sympathetic nervous system.
    Gavras H
    Clin Chem; 1991 Oct; 37(10 Pt 2):1828-30. PubMed ID: 1914197
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Vasopressin antagonists block peripheral as well as central vasopressin receptors.
    De Wied D; Gaffori O; Van Ree JM; De Jong W
    Pharmacol Biochem Behav; 1984 Sep; 21(3):393-400. PubMed ID: 6093152
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Central and systemic effects of a vasopressin V1 antagonist on MAP recovery after haemorrhage in rats.
    Johnson JV; Bennett GW; Hatton R
    J Cardiovasc Pharmacol; 1988 Oct; 12(4):405-12. PubMed ID: 2465440
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Involvement of vasopressin in the cardiovascular effects of intracerebroventricularly administered alpha 1-adrenoceptor agonists in the conscious rat.
    Hiwatari M; Johnston CI
    J Hypertens; 1985 Dec; 3(6):613-20. PubMed ID: 2868056
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The role of vasopressin in the pressor response to bilateral carotid occlusion.
    DiCarlo SE; Stahl LK; Hasser EM; Bishop VS
    J Auton Nerv Syst; 1989 Jun; 27(1):1-10. PubMed ID: 2794340
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hemodynamic effects of antagonists of the vasoconstrictor action of vasopressin in conscious dogs.
    Liard JF; Spadone JC
    J Cardiovasc Pharmacol; 1984; 6(4):713-9. PubMed ID: 6206331
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sex difference in pressor responsiveness to vasopressin and baroreflex function in DOC-salt hypertensive rats.
    Ouchi Y; Share L; Crofton JT; Iitake K; Brooks DP
    J Hypertens; 1988 May; 6(5):381-7. PubMed ID: 3385203
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Vasopressin-central nervous system interactions in the development of DOCA hypertension.
    Berecek KH; Barron KW; Webb RL; Brody MJ
    Hypertension; 1982; 4(3 Pt 2):131-7. PubMed ID: 7068203
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evidence against a pressor role for vasopressin in spontaneous hypertension.
    Sladek CD; Blair ML; Mangiapane M
    Hypertension; 1987 Apr; 9(4):332-8. PubMed ID: 2951326
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.